var data={"title":"Fibrinogen, concentrate from human plasma: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fibrinogen, concentrate from human plasma: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/373470?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fibrinogen-concentrate-from-human-plasma-drug-information\" class=\"drug drug_general\">see &quot;Fibrinogen, concentrate from human plasma: Drug information&quot;</a> and <a href=\"topic.htm?path=fibrinogen-concentrate-from-human-plasma-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fibrinogen, concentrate from human plasma: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6862568\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Fibryga;</li>\n      <li>RiaSTAP</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46226509\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>RiaSTAP</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10575786\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Blood Product Derivative</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10575794\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=fibrinogen-concentrate-from-human-plasma-drug-information\" class=\"drug drug_general\">see &quot;Fibrinogen, concentrate from human plasma: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Target fibrinogen concentration must be individualized for each patient based on the extent of bleeding, laboratory values, and clinical condition of the patient.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Congenital fibrinogen deficiency; treatment of bleeding:</b> Infants, Children, and Adolescents (Kreuz 2005; Manco-Johnson 2009; Riastap prescribing information [UK] 2014):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial dose:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Known baseline fibrinogen level directed dosing: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Dose (mg/kg) = [Target level (mg/dL) - measured level (mg/dL)] <b>divided by</b> 1.7 (mg/dL per mg/kg body weight) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">When baseline fibrinogen level is not known: IV: 70 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adjust dose based on laboratory values and condition of patient. Maintain a target fibrinogen level of 100 mg/dL until hemostasis is achieved.       </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Congenital fibrinogen deficiency, treatment of bleeding:</b> IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">When baseline fibrinogen level is known: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dose (mg/kg) = [Target level (mg/dL) - measured level (mg/dL)] <b>divided by</b> 1.7 (mg/dL per mg/kg body weight) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">When baseline fibrinogen level is not known: 70 mg/kg  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adjust dose based on laboratory values and condition of patient. Maintain a target fibrinogen level of 100 mg/dL until hemostasis is achieved.  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in manufacturer's labeling. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in manufacturer's labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6864450\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, powder for reconstitution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fibryga: ~1 g [exact potency labeled on vial]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">RiaSTAP: 900-1300 mg [contains albumin (human); exact potency labeled on vial]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6864314\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50906636\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=fibrinogen-concentrate-from-human-plasma-drug-information\" class=\"drug drug_general\">see &quot;Fibrinogen, concentrate from human plasma: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Strengths expressed with approximate values. Consult individual vial labels for exact potency within each vial.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10575795\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Infuse slowly at &le;5 mL/minute. Solution should be infused at room temperature. Do not administer with other products or IV solutions. Administrations should be completed within 8 hours after reconstitution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6864359\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 2&deg;C to 25&deg;C (36&deg;F to 77&deg;F) in original carton; do not freeze. Protect from light. RiaSTAP is stable for 8 hours after reconstitution when stored at 20&deg;C to 25&#730;C (68&deg;F to 77&deg;F); Fibryga should be used immediately or within 4 hours after reconstitution, do not refrigerate or freeze. Discard partially used vials.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10575787\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency (afibrinogenemia and hypofibrinogenemia) (FDA approved in pediatric patients [age not specified] and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6864347\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Erythema, pruritus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylaxis, arterial thrombosis, chills, deep vein thrombosis, dyspnea, hypersensitivity reaction, myocardial infarction, nausea, pulmonary embolism, skin rash, thromboembolism</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6864322\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Severe, immediate hypersensitivity reactions, including anaphylaxis to fibrinogen, human plasma-derived products, or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6864343\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions (eg, hives, generalized urticaria, chest tightness, wheezing, hypotension, anaphylaxis) may occur. In the event of hypersensitivity reactions, treatment should be discontinued immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombotic events: Thrombosis may occur spontaneously in patients with congenital fibrinogen deficiency with or without fibrinogen replacement therapy. Thromboembolic events have been reported in patients receiving fibrinogen concentrate. Consider potential risk of thrombosis with use; monitor for signs and symptoms of thrombosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease (eg, viruses and theoretically the Creutzfeldt-Jakob disease [CJD]). Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Not indicated for the treatment of dysfibrinogenemia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299332\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6871911\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=106573&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6864319\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Increased pregnancy loss is associated with untreated congenital fibrinogen disorders (Acharya 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10575796\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Fibrinogen level; signs/symptoms of hypersensitivity and thrombosis  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10575797\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">A target fibrinogen level of 100 mg/dL should be maintained until hemostasis occurs and wound healing is complete.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Normal fibrinogen levels: 200 to 450 mg/dL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6864443\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Fibrinogen (coagulation factor I), a protein found in normal plasma, is required to clot blood. Fibrinogen concentrate made from pooled human plasma replaces this protein which is missing or reduced in patients with a congenital fibrinogen deficiency.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6864361\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: Fibryga: 70.2 &plusmn; 29.9 mL/kg (range: 36.9 to 149.1 mL/kg); RiaSTAP: 52.7 &plusmn; 7.48 mL/kg (range: 36.22 to 67.67 mL/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Similar to biological fibrinogen</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Biological fibrinogen: 100 hours (Kamath 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients &lt;16 years: Initial data suggests decreased compared to adults (Manco-Johnson 2009): 69.9 &plusmn; 8.5 hours (RiaSTAP)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Fibryga: 75.9 &plusmn; 23.8 (40 to 157 hours); RiaSTAP: 78.7 &plusmn; 18.13 hours (range: 55.73 to 117.26 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Clearance faster in pediatric patients &lt;16 years than adults (RiaSTAP)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12992809\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Haemocomplettan (AT, CH, CZ, DE, FR, GR, HN, NL, PT, RO, TR);</li>\n      <li>Haemocomplettan P (TW);</li>\n      <li>RiaSTAP (AU, NZ);</li>\n      <li>Riastap (BE, CY, DK, ES, FR, GB, IE, IS, LU, MT, NO, PL, SE, SI, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Acharya SS and Dimichele DM, &ldquo;Rare Inherited Disorders of Fibrinogen,&rdquo; <i>Haemophilia</i>, 2008, 14(6):1151-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fibrinogen-concentrate-from-human-plasma-pediatric-drug-information/abstract-text/19141154/pubmed\" target=\"_blank\" id=\"19141154\">19141154</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kamath S, Lip GY. Fibrinogen: biochemistry, epidemiology and determinants. <i>QJM</i>. 2003;96(10):711-729.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fibrinogen-concentrate-from-human-plasma-pediatric-drug-information/abstract-text/14500858/pubmed\" target=\"_blank\" id=\"14500858\">14500858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kreuz W, Meili E, Peter-Salonen K, et al. &ldquo;Efficacy and Tolerability of a Pasteurised Human Fibrinogen Concentrate in Patients With Congenital Fibrinogen Deficiency,&rdquo; <i>Transfus Apher Sci</i>, 2005, 32(3):247-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fibrinogen-concentrate-from-human-plasma-pediatric-drug-information/abstract-text/15919240/pubmed\" target=\"_blank\" id=\"15919240\">15919240</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Manco-Johnson MJ, Dimichele D, Castaman G, et al. Pharmacokinetics and safety of fibrinogen concentrate. <i>J Thromb Haemost</i>. 2009;7(12):2064-2069.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fibrinogen-concentrate-from-human-plasma-pediatric-drug-information/abstract-text/19804533 /pubmed\" target=\"_blank\" id=\"19804533 \">19804533 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    RiaSTAP (fibrinogen concentrate [human]) [prescribing information]. Kankakee, IL: CSL Behring, LLC; December 2011.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 106573 Version 26.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F6862568\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F46226509\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10575786\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10575794\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F6864450\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F6864314\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F50906636\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10575795\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F6864359\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10575787\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F6864347\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F6864322\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F6864343\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299332\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6871911\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6864319\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10575796\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F10575797\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F6864443\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F6864361\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F12992809\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/106573|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fibrinogen-concentrate-from-human-plasma-drug-information\" class=\"drug drug_general\">Fibrinogen, concentrate from human plasma: Drug information</a></li><li><a href=\"topic.htm?path=fibrinogen-concentrate-from-human-plasma-patient-drug-information\" class=\"drug drug_patient\">Fibrinogen, concentrate from human plasma: Patient drug information</a></li></ul></div></div>","javascript":null}